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Aim To present the Croatian system of ethical review of 
clinical trials and assessment outcomes of the applications 
reviewed by the Croatian Central Ethics Committee.
Methods Clinical trial applications reviewed by the Croa-
tian Central Ethics Committee, which has the legal man-
date to review clinical trials of medicinal products and 
medical devices, were retrospectively analyzed from May 
2004 to the end of 2008 according to the number, research 
area, and type of opinion issued. Applications from 2008 
were analyzed separately according to the study phase, 
participants (adult trials vs pediatric trials), and sponsor 
(commercial trials vs academic trials). Data were analyzed 
by descriptive statistics.
Results Since its establishment in 2004, the Croatian Cen-
tral Ethics Committee has reviewed 407 trials. The great-
est number of clinical trials was in the field of oncology 
(n = 69), mental and behavioral disorders (n = 52), and en-
docrine, nutritional, and metabolic diseases (n = 50). In 
the initial assessment of clinical trials, 60% applications re-
ceived a conditionally positive opinion. In 28% of applica-
tions, the opinion had to be postponed because additional 
documentation or explanations were required. In 2008, the 
Croatian Central Ethics Committee reviewed 99 trials, most 
of which were phase III trials (n = 57). Five clinical trials in-
cluded pediatric population and 3 were academic clinical 
trials.
Conclusion The model of centralized clinical trial review 
seems to be appropriate for the current number of clini-
cal trials conducted in Croatia. The efficient and standard-
ized review process of clinical trials by the Central Ethics 
Committee may positively affect the increasing number 
of clinical trials conducted in Croatia. Future development 
includes the transparency of the clinical trials through a 
publically available database and establishing the basis for 
conducting academic clinical trials in Croatia. 
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With the adoption of the Directive 2001/20/EC in 2001, 
the implementation of Good Clinical Practice (GCP) in the 
conduct of clinical trials became obligatory for all member 
states of the European Union (1). This directive includes the 
description and enforcement of the responsibilities of Eth-
ics Committees. During the process of clinical trials approval, 
the Ethics Committee assesses relevant documentation sub-
mitted by the applicant, assuring that the rights, safety, and 
well-being of all clinical trial subjects are safeguarded, based 
on which either a positive or negative opinion on a clinical 
trial is issued. After a positive opinion of an ethics committee 
is issued, a competent authority (drug agency, ministry of 
health, etc.) may grant the authorization for a clinical trial.
One of the principles set by the Directive 2001/20/EC was 
the introduction of a single ethics opinion for multi-center 
trials for each member state of the European Union. This 
principle was introduced in order to reduce the delay in the 
commencement of a trial, without jeopardizing the well-be-
ing of the people participating in the trial, and excluding 
the possibility of rejecting it in specific sites (1,2). Although 
the ICH E6 Guideline on GCP, as the internationally adopted 
standard, and the Directive 2001/20/EC, as the legal frame-
work for the conduct of clinical trials in the European Union, 
pose standardized requirements on independent ethics 
committees concerning their roles and responsibilities (1,3), 
it is clear that the process of obtaining a single ethics opin-
ion for multi-center trials in Europe is organized differently 
from country to country. The organization of ethics commit-
tees in Europe can be divided into 3 different models (Table 
1). In the first model, different local ethics committees are 
responsible for giving opinions on single-center trials, while 
for the multi-center trials, one of them is appointed as a sin-
gle-opinion decision maker. In the second model, different 
local ethics committees are responsible for giving opinions 
on single-center trials, while the responsibility for the multi-
center trials is on the central ethics committees. In the third 
model, the responsibility for both single and multi-center tri-
als is on the central ethics committees (4).
Until the beginning of 2004, all opinions on clinical trials in 
Croatia were issued on a local level by the ethics commit-
tees of the institutions in which the clinical trial was con-
ducted. With the first harmonization of the Croatian law 
with the Directive 2001/20/EC, the Croatian Central Ethics 
Committee was established and the second model of the 
review process of clinical trials by the ethics committees 
was accepted (Table 1). This model was changed very soon 
(the end of 2004) and since then, all clinical trials in Croatia, 
both single-center and multi-center, have to be reviewed 
by the Central Ethics Committee (5-8). Since December 
2007, the Central Ethics Committee has also been respon-
sible for issuing opinions on non-interventional trials (9). It 
is important to emphasize that the Central Ethics Commit-
tee has the mandate, according to Croatian law, to review 
clinical trials of medicinal products and medical devices 
but not medical procedures (7-9).
Before the Directive 2001/20/EC came into force, delays 
and diversities in the practice of local ethics committees’ 
assessment of multi-center clinical trials in Europe were 
frequent. The diversities mostly concerned the type of in-
formation required by the committees, committees’ time 
to respond and, what was most important, the final opin-
ion on the same trial (10-13). This unsatisfactory situation 
demanded that some improvements are made in the 
process, and was legally finally overcome by the Direc-
tive. However, even though the Directive ensures that the 
ethical review of a multi-center trial occurs only once and 
within a maximum of 60 days from the application, if differ-
ent local ethics committees act as single-opinion decision 
makers, variations in their work are still inevitable (14,15). 
The aim of our study was to present the Croatian system of 
ethical review of clinical trials and the data on the assess-





The Croatian Central Ethics Committee is an independent 
committee of 19 members appointed by the Minister of 
TabLe 1. organization of review process of clinical trials by the ethics committees in different countries in europe
Review of single-center clinical trial Review of multi-center clinical trial example
Model 1 Local ethics committee Local ethics committee acting as 
single-opinion decision maker
Austria, Belgium, Czech Republic, Denmark, Esto-
nia, Finland, France, Germany, Ireland, Italy, Latvia, 
Netherlands, Norway, Poland, Slovak Republic, 
Spain, Sweden, UK
Model 2 Local ethics committee Central ethics committee Lithuania, Portugal
Model 3 Central ethics committee Central ethics committee Croatia, Cyprus, Greece, Hungary, Malta, Slovenia
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Health and Social Welfare – medical doctors from various 
fields of expertise, a representative of patients, a theologian, 
and a lawyer. It is important to emphasize that the Central 
Ethics Committee assesses both the scientific and ethical 
aspects of clinical trials, assuring that the anticipated ben-
efits and risks for the participants are satisfactory and justi-
fied. In preparing its opinion it considers the trial protocol, 
the investigator’s brochure, the suitability of investigators 
and monitors, the adequacy of facilities, the insurance, the 
methods and amounts of payments, and the methods and 
documents to be used to inform trial subjects and obtain 
their informed consent (9,16). The complete documenta-
tion on a clinical trial is reviewed by two independent ex-
pert assessors, who prepare their recommendations in a 
written form. Every Informed Consent Form is additionally 
assessed by the representative of patients and the theolo-
gian, while the details of insurance and contract between 
the applicant, institution, and principal investigator are also 
verified by the lawyer. The members of the Central Ethics 
Committee, following the interdisciplinary discussion, vote 
for the opinion which is afterwards sent to the applicant. 
There is also a possibility to obtain an external expert opin-
ion when needed. The meetings are held regularly every 2 
to 3 weeks, depending on the number of applications. The 
review process of a clinical trial application by the Croatian 
Central Ethics Committee is presented in Figure 1.
According to the Internal Rules of the Central Ethics Com-
mittee, 4 types of opinions on clinical trials may be issued: 
1) positive opinion; 2) conditionally positive opinion (mi-
nor objections); 3) postponed opinion (major objections 
which ask for additional documentation and explanations); 
and 4) negative opinion.
Data extraction
Clinical trials applications reviewed by the Croatian Central 
Ethics Committee were analyzed retrospectively from May 
2004 to the end of 2008. The gathered data included the 
number of analyzed clinical trials per year, research area, 
and type of opinions issued. Because the new Ordinance 
on Clinical Trials and Good Clinical Practice, which regu-
lates the administrative support of Croatian Agency for 
Medicinal Products and Medical Devices was introduced 
at the end of 2007, clinical trial applications in 2008 were 
analyzed separately according to study phase, participants 
(adult trials vs pediatric trials), and sponsor (commercial tri-
als vs academic trials). Diseases most commonly addressed 
in clinical trials were also classified according to the 10th 
revision of the International Classification of Diseases of 
the World Health Organization (17).
ReSuLTS
Since its establishment in May 2004 until the end of 2008, 
the Central Ethics Committee reviewed 407 trials: 28 in 
May-December 2004, 92 in each 2005 and 2006, 96 in 2007, 
and 99 in 2008. The median number of trials assessed per 
meeting was 7 (range 1-13).
In 2008, the Croatian Central Ethics Committee reviewed 
99 trial applications (Figure 2), most of which were for 
Diagram of review process of clinical trials application by the Croatian Central ethics Committee.
Figure 1.
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phase III trials (n = 57). 5 applications for clinical trials which 
included paediatric population and 3 applications for aca-
demic clinical trials were reviewed.The greatest number of 
trial applications for the whole period was in the field of 
oncology (n = 69), followed by mental and behavioral dis-
orders (n = 52), and endocrine, nutritional, and metabolic 
diseases (n = 50). The first 10 research areas of clinical trials 
assessed by the Central Ethics Committee are presented 
in Figure 3.
The most common initial recommendation by the Cen-
tral Ethics Committee was conditionally positive opinion 
(60%), followed by postponed opinion (28%) (Figure 4). The 
number of postponed opinions increased from 10 in 2006 
to more than 50 in 2008, paralleled by a decrease in the 
number of conditionally positive opinions (Figure 4). The 
number of negative opinions also increased, although their 
numbers remained generally low, less than 5 each year.
DiSCuSSion
The greatest number of trials assessed by the Croatian 
Central Ethics Committee was conducted in the most 
challenging fields of medicine today (oncology, mental 
and behavioral disorders, and endocrine, nutritional and 
metabolic diseases). These 3 research areas are identical to 
those in the study published by the German drug regula-
tory agency (The Federal Institute for Drugs and Medical 
Devices) for the same period (18).
According to our analysis, phase I, II, and IV clinical trials, es-
pecially academic trials and trials on pediatric population, 
are rarely conducted in Croatia. Small number of phase I 
and II trials in Croatia, compared with Germany (30% phase 
I; 27% phase II trial applications) (18), may be explained by 
the absence of innovative pharmaceutical industry in Cro-
atia. However, even with a long history of generic pharma-
ceutical industry in Croatia, the Central Ethics Committee 
did not assess any bioequivalence/bioavailability studies. 
This is probably the result of the type of generic drugs pro-
duction in Croatia, which includes only the final steps in 
the process, and specific requirements in this field, ie, bio-
equivalence/bioavailability studies are performed by the 
Croatian industry only in internationally recognized labo-
ratories with accreditation.
Figure 3.
First  ten  clinical  trials  research  areas  by  number  of  clinical  trials  assessed  by  the 
Croatian  Central  ethics  Committee  (May  2004-2008)  –  classified  according  to  the 
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The number of phase IV trials was very low compared with 
European countries, where they constitute up to 20% of all 
trials in Germany (18) and up to 25% in the United King-
dom (19), but it is expected to increase with an increase in 
the number of academic trials. The small number of aca-
demic clinical trials is probably the result of a lack of finan-
cial and institutional support, but also the consequence 
of the growing complexity of the requirements for clini-
cal trials, which include the demands of GCP (Directive 
2001/20/EC). An investigation at the university hospital in 
Austria found 66% decrease in academic research after the 
introduction of the Directive, while the number of indus-
try-sponsored clinical trials remained constant (20). On the 
other hand, there has been no decline in the number of 
academic clinical trials in Denmark, and the explanation is 
in the established system of GCP units, ie, university and 
university hospital GCP units provide free assistance to aca-
demic clinical researchers (21).
Although the number of clinical trials with pediatric popu-
lation in 2008 was small (n = 5), it can be expected that it 
will increase in near future because of the Pediatric Regula-
tion, which came to force in the European Union in Janu-
ary 2007 (22).
A considerable increase in the number of opinions which 
had to be postponed due to major objections in 2007, and 
even greater in 2008, may be attributed to the changes in 
the legislation at the end of 2007, which introduced spe-
cific requirements for investigators, monitors, contracts, 
and insurance (9). This legislative change introduced the 
need for the Central Ethics Committee approval of non-
interventional trials, and is aimed at preventing trials con-
ducted primarily for marketing purposes (9).
The advantages of the centralized review process of clini-
cal trials by the ethics committee, based on the experience 
of the Croatian Central Ethics Committee, are the follow-
ing: single application form, standardized requirements, 
standardized assessment, no variations in time-to-respond, 
single point of contact, and a single database of clinical 
trials. If sufficiently equipped and funded to take the re-
sponsibility, this model allows efficient and standardized 
assessment of clinical trials suitable for countries similar to 
Croatia according to the number of inhabitants and clinical 
trials per year. The efficient review process of clinical trials 
by the Central Ethics Committee may increase the number 
of clinical trials conducted in Croatia. There is certainly a 
room for future development, which includes increasing 
the transparency of the clinical trials through a publical-
ly available database, according to the EU guidelines (23). 
Further, there is a possibility and a need for specific GCP 
education units which would promote academic clinical 
trials.
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